共 50 条
- [21] ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancersCANCER RESEARCH, 2023, 83 (08)Shpektor, DianaDargahi, DaryanazSamiotakis, AntoniosWienke, SaraLivernois, AliYablonovitch, ArielleYalamanchili, GeethikaGartner, ElainaMeric-Bernstam, Funda
- [22] BIOMARKER ANALYSIS OF A PHASE 1 STUDY OF MM-111, A BISPECIFIC HER2/HER3 ANTIBODY FUSION PROTEIN, IN COMBINATION WITH MULTIPLE TREATMENT REGIMENS IN PATIENTS WITH ADVANCED HER2 POSITIVE SOLID TUMORSANNALS OF ONCOLOGY, 2014, 25Kudla, A.Adiwijaya, B.Paragas, V.Richards, D.Braiteh, F.Garcia, A. A.Denlinger, C. S.Conkling, P.Edenfield, W. J.Anthony, S.Hellerstedt, B.Raju, R.Becerra, C.Harb, W.Smith, D.Kawash, K.Frye, S.McDonagh, C. F.Moyo, V.
- [23] TAA013 a trastuzumab antibody drug conjugate phase I dose escalation study in recurrent her2 positive breast cancerCANCER RESEARCH, 2021, 81 (04)Liu, J. M.Yin, Y. M.Wu, HaoLi, W.Huang, X.Li, X. X.
- [24] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours.JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 127S - 127SShaw, H.Plummer, R.Vidal, L.Perrett, R.Pilkington, M.Temple, G.Fong, P.Amelsberg, A.Calvert, H.De Bono, J.
- [25] A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrationsEUROPEAN JOURNAL OF CANCER, 2022, 174 : S1 - S1Opdam, F.Heymach, J.Barve, M.Wu, Y. L.Gibson, N.Sadrolhefazi, B.Serra, J.Yoh, K.Yamamoto, N.
- [26] Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+breast cancer model (SKBR3)ANTI-CANCER DRUGS, 2020, 31 (05) : 463 - 472Rodallec, AnneSicard, GuillaumeGiacometti, SarahCarre, ManonMaia, ThomasValette, MargauxBouquet, FannySavina, ArielLacarelle, BrunoCiccolini, JosephFanciullino, Raphaelle
- [27] Phase I study of GQ1005, a new generation HER2-ADC, in patients with HER2-expressing and HER2 mutated advanced solid tumorsCANCER RESEARCH, 2024, 84 (07)Zhou, CaicunYang, BoDeng, TingWang, BiyunZhang, JianSun, YupingWang, LinlinYang, HongweiWang, JingfenLi, WeiSong, QiYang, Yuchong
- [28] Can HER2 1+Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast CancerCANCERS, 2022, 14 (17)Shu, LanTong, YiweiLi, ZhuoxuanChen, XiaosongShen, Kunwei
- [29] The HER2-RADiCAL study (Response ADaptive CAre pLan) - Tailoring treatment for HER2 positive early breast cancerCANCER RESEARCH, 2024, 84 (09)Macpherson, IainMcIntosh, StuartKilburn, LucyTovey, HollyMoretti, LauraGoddard, KatieBhattacharya, IndraniBoyd, ClintonKirwan, ClionaO'Brien, CiaraWheatley, DuncanGlendenning, JenniferMacKenzie, MaireadStobart, HilarySnowdon, ClaireWardley, AndrewShaaban, AbeerHall, PeterCameron, DavidBliss, Judith
- [30] The HER2-RADiCAL study (Response ADaptive CAre pLan) - Tailoring treatment for HER2 positive early breast cancerCANCER RESEARCH, 2022, 82 (04)Macpherson, IainMcIntosh, StuartKilburn, LucyTovey, HollyKernaghan, SarahGoddard, KatieBhattacharya, IndraniBoyd, ClintonColes, CharlotteKirwan, ClionaMackenzie, MaireadO'Brien, CiaraRing, AlistairSnowdon, ClaireStobart, HilaryWheatley, DuncanWardley, AndrewShaaban, AbeerHall, PeterCameron, DavidBliss, Judith